Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Effects of combination lipid therapy in type 2 diabetes mellitus.

ACCORD Study Group., Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP.

N Engl J Med. 2010 Apr 29;362(17):1563-74. doi: 10.1056/NEJMoa1001282. Epub 2010 Mar 14. Erratum in: N Engl J Med. 2010 May 6;362(18):1748.

2.

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.

Keating GM.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Review.

PMID:
21675801
3.

Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.

Filippatos TD, Elisaf MS.

Expert Opin Pharmacother. 2011 Aug;12(12):1945-58. doi: 10.1517/14656566.2011.593509. Epub 2011 Jul 8. Review.

PMID:
21736529
4.

Do persons with diabetes benefit from combination statin and fibrate therapy?

Rosenblit PD.

Curr Cardiol Rep. 2012 Feb;14(1):112-24. doi: 10.1007/s11886-011-0237-7. Review.

PMID:
22213157
5.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
6.

A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.

Aguiar C, Alegria E, Bonadonna RC, Catapano AL, Cosentino F, Elisaf M, Farnier M, Ferrières J, Filardi PP, Hancu N, Kayikcioglu M, Mello E Silva A, Millan J, Reiner Ž, Tokgozoglu L, Valensi P, Viigimaa M, Vrablik M, Zambon A, Zamorano JL, Ferrari R.

Atheroscler Suppl. 2015 Sep;19:1-12. doi: 10.1016/S1567-5688(15)30001-5.

PMID:
26315511
7.

Fenofibrate: a review of its use in dyslipidaemia.

McKeage K, Keating GM.

Drugs. 2011 Oct 1;71(14):1917-46. doi: 10.2165/11208090-000000000-00000. Review.

PMID:
21942979
8.

Fibrates after the FIELD study: Some answers, more questions.

Wierzbicki AS.

Diab Vasc Dis Res. 2006 Dec;3(3):166-71. Review.

PMID:
17160911
9.

HMG CoA reductase inhibitors (statins) for kidney transplant recipients.

Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2014 Jan 28;(1):CD005019. doi: 10.1002/14651858.CD005019.pub4. Review.

PMID:
24470059
10.

More clinical lessons from the FIELD study.

Fazio S.

Cardiovasc Drugs Ther. 2009 Jun;23(3):235-41. doi: 10.1007/s10557-008-6160-5. Review.

PMID:
19160032
11.
12.

Fibrates for secondary prevention of cardiovascular disease and stroke.

Wang D, Liu B, Tao W, Hao Z, Liu M.

Cochrane Database Syst Rev. 2015 Oct 25;(10):CD009580. doi: 10.1002/14651858.CD009580.pub2. Review.

PMID:
26497361
13.

[Diabetic dyslipidaemia and the atherosclerosis].

Márk L, Dani G.

Orv Hetil. 2016 May 8;157(19):746-52. doi: 10.1556/650.2016.30441. Review. Hungarian.

PMID:
27133274
14.

Safety considerations with fenofibrate/simvastatin combination.

Filippatos TD, Elisaf MS.

Expert Opin Drug Saf. 2015;14(9):1481-93. doi: 10.1517/14740338.2015.1056778. Epub 2015 Jul 3. Review.

PMID:
26134595
15.
16.
17.
18.

Hyperlipidaemia and cardiovascular disease: do fibrates have a role?

Saha SA, Arora RR.

Curr Opin Lipidol. 2011 Aug;22(4):270-6. doi: 10.1097/MOL.0b013e32834701c3. Review.

PMID:
21519250
19.

Myopathy with statin-fibrate combination therapy: clinical considerations.

Jacobson TA.

Nat Rev Endocrinol. 2009 Sep;5(9):507-18. doi: 10.1038/nrendo.2009.151. Epub 2009 Jul 28. Review.

PMID:
19636324
20.

Fenofibrate and metabolic syndrome.

Kraja AT, Province MA, Straka RJ, Ordovas JM, Borecki IB, Arnett DK.

Endocr Metab Immune Disord Drug Targets. 2010 Jun;10(2):138-48. Review.

Supplemental Content

Support Center